Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DATA: Denosumab and Teriparatide in Osteoporosis
NCT00926380Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2009
- Primary completion
- Dec 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab and teriparatide in osteoporosis (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Spine Bone Density at 2 years. Started Jun 2009; status: completed.
02
Drugs
denosumabteriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00926380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00926380.